胃癌患者血清可溶性白细胞介素－2受体初步研究

PRELIMINARYSTUDIESONSERUMsI L- 2RLEVELS INPATIENTSWITHGASTRICCANCER

应用双抗体夹心ＥＬＩＳＡ法对３０例胃癌患者血清ｓＩＬ－２Ｒ水平进行测定。结果表明，胃癌患者血清ｓＩＬ－２Ｒ水平明显高于正常对照（Ｐ＜０．０１）及慢性良性胃病患者（Ｐ＜０．０５）；Ⅲ－Ⅳ期患者血清ｓＩＬ－２Ｒ水平显著高于Ⅰ－Ⅱ期患者（Ｐ＜０．０５）；低度分化者较中度分化者ｓＩＬ－２Ｒ水平明显升高（Ｐ＜００１）；贲门癌患者ｓＩＬ－２Ｒ水平较胃窦（体）癌者高，但未达到统计学差别（Ｐ＞０．０５）；胃癌根治术后一周血清ｓＩＬ－２Ｒ水平较术前升高（Ｐ＜０．０１），术后二周血清ｓＩＬ－２Ｒ较术前明显降低（Ｐ＜０．０１），与正常人相比无明显差异（Ｐ＞００５）。结果提示血清ｓＩＬ－２Ｒ测定可作为胃癌患者病情判断、观察疗效及估价预后新的生物学指标。

Abstract。Serum sIL-2R levels of 30 patients with gastric cancer were detected by using a sandwichELISA. The results showed that the mean level of serum sIL- 2R of gastric cancer patients wasmuch higher than that of healthy subjects(P<0.01) and that of benign disorders(P<0.05),and serum sIL-2R levels of stageⅢ-Ⅳ patients were significantly higher than that of stage I-ⅡPatients(P< 0.05).sIL-2R levels in patients with poorly-differentiated cancers were alsohigher than those in patients with moderately differentiated cancers(P< 0.01).Radicaloperation had very important effect on the levels of serum sIL- 2R (P< 0.01).It can beconcluded that serum sIL-2R level assay is a new biological marker for the assessment of thestage,the response to medical intervention and the prognosis in gastric cancer。